Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2023

Kojima Kensuke

Abstract excerpt

Anthracycline- and cytarabine-based intensive combination chemotherapies are considered the backbone therapy for patients with acute myeloid leukemia (AML). Although chemotherapy leads to long-term remission and cures many patients with AML, it can induce DNA damage/stress due to acute/chronic toxicities, acquired resistance, relapse, and therapy-related malignancies. Introduction of molecularly targeted agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents
Share to Clinical Relevance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37793871
DOI: 10.11406/rinketsu.64.955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].PMID 37793871Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.Semantic proximity Read ↗

Molecular and Clinical Insights into TP53-Mutated MDS and AML.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Semantic proximity Read ↗

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionSemantic proximity Read ↗

Comparison of<i>TP53</i>Mutations in Myelodysplasia and Acute Leukemia Suggests Divergent Roles in Initiation and ProgressionSemantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Targeting TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.